TNXP Tonix Pharmaceuticals Holding Corp. - Common Stock
$12.79
价格 · 八月 19, 2026
截至...的财报数据 八月 10, 2026
52周区间
$9–$39
11% of range
分析师评级
BUY
10 analysts
目标价
$42
+232% upside
P/E (TTM)
-0.9
ROE
-60.0%
净利润率
-946.2%
TNXP 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$12.79
市值
$164M
P/E (TTM)
-0.9
每股收益 (TTM)
$-14.57
营收 (TTM)
$13M
股息收益率
—
ROE
-60.0%
负债/权益
—
52周区间
$9 – $39
TNXP 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
$13M
2023-12-31
→
2025-12-31
EPS
$-14.57
2021-12-31
→
2025-12-31
自由现金流
$-103M
2017-12-31
→
2025-12-31
利润率
-946.2%
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
TNXP
同行中位数
P/E (TTM)
-0.9
1.2
P/S (TTM) (市销率 (TTM))
12.5
9.3
P/B (市净率)
0.7
1.6
Price / FCF (股价/自由现金流)
-1.6
—
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
TNXP
同行中位数
Operating Margin (营业利润率)
-959.1%
—
Net Profit Margin (净利润率)
-946.2%
-411.2%
ROA
-56.4%
-52.7%
ROE
-60.0%
-77.3%
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
TNXP
同行中位数
Current Ratio (流动比率)
7.4
7.4
Quick Ratio (速动比率)
6.9
—
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
TNXP
同行中位数
Revenue YoY (营收同比增长)
29.8%
—
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
TNXP
同行中位数
TNXP 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
买入
10 位分析师
- 强烈买入 3 30.0%
- 买入 6 60.0%
- 持有 1 10.0%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
5 位分析师 · 2026-08-17
中位数
$34.00
平均值
$42.40
← 低于所有目标
$12.79
最低
$22.00
最高
$65.00
中位数目标
$34.00
+165.8%
平均目标
$42.40
+231.5%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-0.15%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $-2.44 | $-2.75 | 0.31% |
| 2026年3月31日 | $-2.93 | $-2.48 | -0.45% |
| 2025年12月31日 | $-3.98 | $-3.25 | -0.73% |
| 2025年9月30日 | $-3.59 | $-3.66 | 0.07% |
| 2025年6月30日 | $-3.86 | $-3.28 | -0.58% |
| 2025年3月31日 | $-2.84 | $-3.29 | 0.45% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| TNXP | $200M | -1.1 | 29.8% | -946.2% | -60.0% | — |
| NERV | $174M | -0.1 | — | — | 339.5% | — |
| RNA | $10.91B | -14.5 | 72.1% | -3650.4% | -47.5% | — |
| CNXU | — | — | — | — | — | — |
| IMUX | — | -0.9 | — | — | — | — |
| NBP | — | — | — | — | — | — |
| ABOS | $128M | -1.1 | — | — | -129.4% | — |
| KROS | $398M | 8.9 | — | 35.7% | 17.2% | — |
| KRRO | $75M | -0.6 | 181.5% | -1834.5% | -140.8% | — |
| WHWK | $114M | -7.3 | -72.5% | -288.3% | -13.4% | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 14
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $13M | $10M | $8M | |
| Cost of Revenue | $7M | $8M | $5M | |
| R&D Expense | $44M | $40M | $87M | |
| SG&A Expense | $88M | $40M | $35M | |
| Operating Expenses | $139M | $147M | $126M | |
| Operating Income | $-126M | $-137M | $-118M | |
| Interest Income | $4M | $22.0K | $2M | |
| Other Non-op | $-3M | $-867.0K | $2M | |
| Net Income | $-124M | $-130M | $-117M | |
| EPS (Basic) | $-14.57 | $-176.60 | $-14720.25 | |
| EPS (Diluted) | $-14.57 | $-176.60 | $-14720.25 | |
| Shares (Basic) | 8,511,318 | 736,339 | 7,925 | |
| Shares (Diluted) | 8,511,318 | 736,339 | 7,925 | |
| EBITDA | $-124M | $-133M | $-114M |
资产负债表 25
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & Equivalents | $208M | $99M | $25M | |
| Receivables | $6M | $4M | · | |
| Inventory | · | $8M | $14M | |
| Prepaid Expense | $9M | $8M | $9M | |
| Other Current Assets | · | · | $2M | |
| Current Assets | $229M | $119M | $48M | |
| PP&E (Net) | $44M | $42M | $94M | |
| PP&E (Gross) | $50M | $46M | $99M | |
| Accum. Depreciation | $6M | $4M | $5M | |
| Goodwill | · | · | $965.0K | |
| Intangibles | $120.0K | $120.0K | $10M | |
| Other Non-current Assets | $2M | $951.0K | $1M | |
| Total Assets | $277M | $163M | $154M | |
| Accounts Payable | $8M | $5M | $4M | |
| Current Liabilities | $31M | $18M | $19M | |
| Capital Leases | $1M | $358.0K | $632.0K | |
| Total Liabilities | $32M | $23M | $49M | |
| Long-term Debt | · | $9M | $11M | |
| Total Debt | · | $7M | $9M | |
| Common Stock | $13.0K | $4.0K | · | |
| Retained Earnings | $-855M | $-731M | $-601M | |
| AOCI | $-289.0K | $-255.0K | $-232.0K | |
| Stockholders' Equity | $245M | $140M | $106M | |
| Liabilities + Equity | $277M | $163M | $154M | |
| Shares Outstanding | 12,788,069 | 4,385,929 | 20,926 |
现金流 14
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| D&A | $2M | $3M | $4M | |
| Stock-based Comp | $6M | $5M | $9M | |
| Amort. of Intangibles | $0 | $500.0K | $477.0K | |
| Other Non-cash | $16M | $61M | $1M | |
| Operating Cash Flow | $-100M | $-61M | $-102M | |
| CapEx | $3M | $120.0K | $8M | |
| Investing Cash Flow | $-5M | $-120.0K | $-29M | |
| Net Debt Issued | $-10M | $-2M | · | |
| Stock Issued | $238M | $140M | $19M | |
| Stock Repurchased | $14M | · | $14M | |
| Net Stock Activity | $224M | $140M | $5M | |
| Financing Cash Flow | $215M | $135M | $37M | |
| Net Change in Cash | $110M | $74M | $-95M | |
| Free Cash Flow | $-103M | $-61M | $-110M |
盈利能力 5
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Operating Margin | -959.1% | -1354.3% | -1523.9% | |
| Net Margin | -946.2% | -1288.2% | -1501.8% | |
| EBITDA Margin | -944.4% | -1320.4% | -1468.7% | |
| ROA | -56.4% | -82.0% | -61.4% | |
| ROE | -60.0% | -121.7% | -103.1% |
流动性与偿付能力 4
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Current Ratio | 7.4 | 6.5 | 2.5 | |
| Quick Ratio | 6.9 | 5.6 | 1.3 | |
| Debt / Equity | · | 0.1 | 0.1 | |
| LT Debt / Equity | · | 0.0 | 0.1 |
效率 3
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | 0.0 | |
| Inventory Turnover | · | 0.7 | 0.7 | |
| Receivables Turnover | 2.6 | 5.5 | · |
增长率 1
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue YoY | 29.8% | 29.9% | · |
估值 (TTM) 14
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue TTM | $13M | $10M | $8M | |
| Net Income TTM | $-124M | $-130M | $-117M | |
| Market Cap | $200M | $145M | $75.03B | |
| Enterprise Value | · | $53M | $75.01B | |
| P/E | -1.1 | -0.2 | -0.1 | |
| P/S | 15.2 | 14.3 | 9658.4 | |
| P/B | 0.8 | 1.0 | 711.0 | |
| P / Tangible Book | 0.8 | 1.0 | 791.3 | |
| P / Cash Flow | -2.0 | -2.4 | -735.5 | |
| P / FCF | -1.9 | -2.4 | -682.7 | |
| EV / EBITDA | · | -0.4 | -657.5 | |
| EV / FCF | · | -0.9 | -682.5 | |
| EV / Revenue | · | 5.3 | 9656.4 | |
| Earnings Yield | -93.3% | -535.1% | -1150.0% |
损益表 14
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $7M | $5M | $3M | $2M | $2M | $3M | $3M | $2M | $2M | $4M | $4M | |
| Cost of Revenue | $703.0K | $2M | $1M | $1M | $3M | $943.0K | $1M | $2M | $3M | $2M | $2M | $2M | |
| R&D Expense | $19M | $18M | $17M | $9M | $11M | $7M | $8M | $9M | $10M | $13M | $17M | $21M | |
| SG&A Expense | $36M | $29M | $36M | $26M | $16M | $10M | $16M | $8M | $8M | $9M | $12M | $9M | |
| Operating Expenses | $56M | $48M | $54M | $36M | $30M | $18M | $25M | $18M | $80M | $24M | $31M | $32M | |
| Operating Income | $-43M | $-42M | $-48M | $-33M | $-28M | $-16M | $-22M | $-16M | $-77M | $-21M | $-27M | $-28M | |
| Interest Income | · | $1M | $1M | $1M | · | $394.0K | $1.0K | $18.0K | · | · | · | $172.0K | |
| Other Non-op | $-49.0K | $-3.0K | $-578.0K | $-1M | $-2M | · | $376.0K | $-44.0K | $-606.0K | $-593.0K | $7.0K | $172.0K | |
| Net Income | $-41M | $-40M | $-47M | $-32M | $-28M | $-17M | $-22M | $-14M | $-79M | $-15M | $-27M | $-28M | |
| EPS (Basic) | $-2.44 | $-2.93 | $-4.28 | $-3.59 | $-3.86 | $-2.84 | $2302.65 | $-22.68 | $-1920.85 | $-535.72 | $-14629.18 | $-38.63 | |
| EPS (Diluted) | $-2.44 | $-2.93 | $-4.28 | $-3.59 | $-3.86 | $-2.84 | $2302.65 | $-22.68 | $-1920.85 | $-535.72 | $-14629.18 | $-38.63 | |
| Shares (Basic) | 16,635,254 | 13,707,104 | -13,665,962 | 8,922,792 | 7,327,257 | 5,927,231 | 40,773 | 626,669 | 41,011 | 27,886 | -11,560,812 | 724,190 | |
| Shares (Diluted) | 16,635,254 | 13,707,104 | -13,665,962 | 8,922,792 | 7,327,257 | 5,927,231 | 40,773 | 626,669 | 41,011 | 27,886 | -11,560,812 | 724,190 | |
| EBITDA | $-43M | $-41M | · | $-33M | $-28M | $-16M | · | $-16M | $-77M | $-20M | · | $-28M |
资产负债表 25
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $176M | $185M | $208M | $190M | $125M | $132M | $99M | $28M | $4M | $7M | $25M | $7M | |
| Receivables | $12M | $9M | $6M | $3M | $2M | $3M | $4M | $4M | $3M | · | · | $2M | |
| Inventory | · | · | · | · | · | · | · | $8M | $9M | $12M | $14M | $13M | |
| Prepaid Expense | $11M | $9M | $9M | $9M | $10M | $6M | $8M | $10M | $8M | $11M | $9M | $10M | |
| Other Current Assets | · | · | · | · | · | · | · | $2M | · | · | · | · | |
| Current Assets | $203M | $207M | $229M | $208M | $144M | $150M | $119M | $51M | $25M | $30M | $48M | $31M | |
| PP&E (Net) | $45M | $45M | $44M | $43M | $42M | $42M | $42M | $43M | $43M | $93M | $94M | $95M | |
| PP&E (Gross) | $52M | $51M | $50M | $48M | $47M | $46M | $46M | $46M | $46M | $99M | $99M | $99M | |
| Accum. Depreciation | $7M | $7M | $6M | $6M | $5M | $5M | $4M | $4M | $3M | $6M | $5M | $4M | |
| Goodwill | · | · | · | · | · | · | · | · | · | $965.0K | $965.0K | $965.0K | |
| Intangibles | $120.0K | $120.0K | $120.0K | $120.0K | $120.0K | $120.0K | $120.0K | $120.0K | $120.0K | $10M | $10M | $10M | |
| Other Non-current Assets | $5M | $4M | $2M | $1M | $931.0K | $910.0K | $951.0K | $951.0K | $961.0K | $960.0K | $1M | $1M | |
| Total Assets | $254M | $258M | $277M | $252M | $187M | $193M | $163M | $95M | $70M | $135M | $154M | $139M | |
| Accounts Payable | $9M | $10M | $8M | $9M | $8M | $4M | $5M | $4M | $10M | $7M | $4M | $8M | |
| Current Liabilities | $31M | $30M | $31M | $21M | $19M | $12M | $18M | $15M | $22M | $20M | $19M | $18M | |
| Capital Leases | $1M | $1M | $1M | $266.0K | $297.0K | $328.0K | $358.0K | $425.0K | $493.0K | $563.0K | $632.0K | $716.0K | |
| Total Liabilities | $32M | $31M | $32M | $21M | $19M | $12M | $23M | $21M | $28M | $27M | $49M | $18M | |
| Long-term Debt | · | · | · | · | · | · | $9M | $9M | $10M | $11M | $11M | · | |
| Total Debt | · | · | · | · | · | · | · | $8M | $8M | $9M | · | · | |
| Common Stock | $17.0K | $14.0K | $13.0K | $10.0K | $8.0K | $7.0K | $4.0K | $156.0K | $10.0K | $74.0K | · | $18.0K | |
| Retained Earnings | $-935M | $-895M | $-855M | $-808M | $-776M | $-748M | $-731M | $-709M | $-694M | $-616M | $-601M | $-573M | |
| AOCI | $-348.0K | $-283.0K | $-289.0K | $-274.0K | $-270.0K | $-266.0K | $-255.0K | $-250.0K | $-243.0K | $-240.0K | $-232.0K | $-220.0K | |
| Stockholders' Equity | $222M | $227M | $245M | $231M | $168M | $180M | $140M | $74M | $42M | $108M | $106M | $121M | |
| Liabilities + Equity | $254M | $258M | $277M | $252M | $187M | $193M | $163M | $95M | $70M | $135M | $154M | $139M | |
| Shares Outstanding | 16,792,317 | 14,205,401 | 12,788,069 | 10,168,204 | 7,546,276 | 6,877,816 | 4,385,929 | 155,631,049 | 9,832,587 | 73,724,196 | 20,926 | 17,762,341 |
现金流 14
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $619.0K | $555.0K | $488.0K | $461.0K | $483.0K | $493.0K | $496.0K | $510.0K | $1M | $1M | $1M | $1M | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $1M | $882.0K | $894.0K | $1M | $1M | $2M | $2M | $2M | |
| Amort. of Intangibles | · | $0 | $0 | $0 | · | $0 | $100.0K | $0 | $200.0K | $200.0K | · | $238.0K | |
| Other Non-cash | · | $-5M | · | · | · | $-1M | · | · | · | $-6M | · | · | |
| Operating Cash Flow | $-42M | $-42M | $-40M | $-29M | $-15M | $-17M | $-15M | $-19M | $-10M | $-18M | $-22M | $-23M | |
| CapEx | $587.0K | $2M | $2M | $962.0K | $527.0K | $6.0K | $3.0K | $9.0K | $0 | $108.0K | $438.0K | $2M | |
| Investing Cash Flow | $-587.0K | $-2M | $-1M | $-962.0K | $-3M | $-6.0K | $-3.0K | $-9.0K | $0 | $-108.0K | $-431.0K | $-821.0K | |
| Net Debt Issued | · | · | · | · | · | $-10M | · | · | · | $-235.0K | · | · | |
| Stock Issued | $33M | $20M | $67M | $95M | $14M | $62M | $86M | $44M | · | · | $9M | $6M | |
| Stock Repurchased | · | · | $8M | $0 | $3M | $3M | · | · | · | · | $0 | $0 | |
| Net Stock Activity | · | $20M | · | · | $-3M | $59M | · | · | · | · | · | · | |
| Financing Cash Flow | $34M | $20M | $59M | $95M | $11M | $50M | $85M | $43M | $7M | $-212.0K | $41M | $6M | |
| Net Change in Cash | $-9M | $-24M | $18M | $65M | $-6M | $33M | $71M | $24M | $-3M | $-18M | $18M | $-18M | |
| Free Cash Flow | · | $-44M | · | · | · | $-17M | · | · | · | $-18M | · | · |
盈利能力 5
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -314.1% | -603.9% | · | -1005.1% | -1416.2% | -660.9% | · | -551.2% | -3501.6% | -860.2% | · | -705.6% | |
| Net Margin | -299.4% | -584.4% | · | -972.9% | -1415.0% | -692.8% | · | -503.7% | -3567.8% | -601.9% | · | -701.3% | |
| EBITDA Margin | -314.1% | -595.8% | · | -1005.1% | -1416.2% | -640.6% | · | -551.2% | -3501.6% | -811.5% | · | -705.6% | |
| ROA | -18.4% | -17.8% | · | -18.4% | -21.9% | -10.2% | · | -12.1% | -68.5% | -9.5% | · | -14.6% | |
| ROE | -20.8% | -19.7% | · | -21.0% | -26.9% | -11.7% | · | -14.6% | -86.3% | -10.9% | · | -16.0% |
流动性与偿付能力 4
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.6 | 7.0 | · | 9.9 | 7.5 | 12.3 | · | 3.3 | 1.1 | 1.5 | · | 1.8 | |
| Quick Ratio | 6.1 | 6.6 | · | 9.2 | 6.7 | 11.1 | · | 2.1 | 0.3 | 0.3 | · | 0.5 | |
| Debt / Equity | · | · | · | · | · | · | · | 0.1 | 0.2 | 0.1 | · | · | |
| LT Debt / Equity | · | · | · | · | · | · | · | 0.1 | 0.1 | 0.1 | · | · |
效率 3
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | · | · | · | · | · | · | · | 0.1 | 0.3 | 0.3 | · | 0.4 | |
| Receivables Turnover | 1.9 | 1.1 | · | 0.9 | 0.7 | 1.5 | · | 1.0 | 1.3 | · | · | 5.1 |
估值 (TTM) 14
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $26M | $15M | · | $11M | $9M | $10M | · | $12M | · | · | · | · | |
| Net Income TTM | $-141M | $-117M | · | $-91M | $-138M | $-125M | · | $-136M | $-150M | $-104M | · | $-118M | |
| Market Cap | $214M | $195M | · | $246M | $272M | $123M | · | $2.33B | $688M | $44.82B | · | $31.26B | |
| Enterprise Value | · | · | · | · | · | · | · | $2.31B | $693M | $44.83B | · | · | |
| P/E | -1.0 | -1.0 | · | -0.7 | -0.0 | -0.0 | · | -0.0 | -0.0 | -1.0 | · | -18.5 | |
| P/S | 8.3 | 13.4 | · | 23.3 | 28.7 | 12.4 | · | 203.0 | · | · | · | · | |
| P/B | 1.0 | 0.9 | · | 1.1 | 1.6 | 0.7 | · | 31.5 | 16.3 | 414.5 | · | 258.7 | |
| P / Tangible Book | 1.0 | 0.9 | · | 1.1 | 1.6 | 0.7 | · | 31.5 | 16.4 | 458.9 | · | 284.5 | |
| P / Cash Flow | · | -4.6 | · | · | · | -7.4 | · | · | · | -2550.5 | · | · | |
| P / FCF | · | -4.4 | · | · | · | -7.4 | · | · | · | -2534.9 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | -148.8 | -9.0 | -2225.6 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | · | -2535.0 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | 201.2 | · | · | · | · | |
| Earnings Yield | -100.5% | -96.2% | · | -136.5% | -5420.3% | -13881.9% | · | -16785.9% | -3634.9% | -103.1% | · | -5.4% |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 收入 | $13M | $10M | $8M | — | — |
| 营业利润率 % | -959.1% | -1354.3% | -1523.9% | — | — |
| 净收入 | $-124M | $-130M | $-117M | $-110M | $-92M |
| 稀释后每股收益 (EPS) | $-14.57 | $-176.60 | $-14720.25 | $-20.01 | $-8.10 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 负债/股东权益比率 | — | 0.1 | 0.1 | — | — |
| 流动比率 | 7.4 | 6.5 | 2.5 | 7.2 | 8.7 |
| 速动比率 | 6.9 | 5.6 | 1.3 | 6.6 | 8.2 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | $-103M | $-61M | $-110M | $-146M | $-111M |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 112 家申报者 · $99.5M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 34 (+13 与上一季度对比) | 5 (-1 与上一季度对比) | 46 (+11 与上一季度对比) | 12 (-2 与上一季度对比) | +3.4M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
公司内部人士 22 位内幕人士 · 5 位高管 · 6 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Seth Lederman | Chief Executive Officer | 2026年6月9日 P | 9005 | 1 | 0 | $58950 |
| Bradley Saenger | Chief Financial Officer | 2026年6月30日 J | 2154 | 0 | 0 | $0 |
| Leland Gershell | Chief Financial Officer | 2015年9月28日 P | 19260 | 0 | 0 | $0 |
| Bruce Daugherty | Chief Scientific Officer and Secretary | 2016年2月9日 A | 57768 | 0 | 0 | $0 |
| Donald J Kellerman | Senior Vice President, Clinical Development and Medical Affairs | 2014年10月29日 A | — | 0 | 0 | $0 |
| Carolyn E. Taylor | 董事 | 2026年6月12日 P | 1833 | 1 | 0 | $14928 |
| Richard Newcomb Stillwell | 董事 | 2026年6月8日 P | 5000 | 1 | 0 | $58250 |
| Stuart Davidson | 董事 | 2016年5月27日 A | 1490716 | 0 | 0 | $0 |
| Samuel R Saks | 董事 | 2016年5月27日 A | 32550 | 0 | 0 | $0 |
| Ernest Mario | 董事 | 2016年5月27日 A | 380724 | 0 | 0 | $0 |
| James Treco | — | 2023年5月8日 A | 10000 | 0 | 0 | $0 |
| Margaret Smith Bell | — | 2022年5月9日 A | 5391 | 0 | 0 | $0 |
| Richard H Bagger | — | 2022年5月9日 A | 10000 | 0 | 0 | $0 |
| David L Grange | — | 2022年5月9日 A | — | 0 | 0 | $0 |
| Adeoye Y Olukotun | — | 2022年5月9日 A | 5350 | 0 | 0 | $0 |
| Jessica Edgar Morris | — | 2022年2月15日 A | — | 0 | 0 | $0 |
| Gregory M Sullivan | — | 2022年2月15日 A | 62727 | 0 | 0 | $0 |
| Daniel Wintner Goodman | — | 2021年5月25日 P | 5001 | 0 | 0 | $0 |
| John B Rhodes | — | 2020年5月4日 A | 81196 | 0 | 0 | $0 |
| Donald W Landry | — | 2019年5月6日 A | — | 0 | 0 | $0 |
| Patrick P Grace | — | 2019年5月6日 A | — | 0 | 0 | $0 |
| Charles E Mather IV | — | 2016年5月27日 A | 11830 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
激进投资者及 5%+ 股东 1 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Seth Lederman, Lederman & Co., LLC, L&L Technologies, LLC, Targent Pharmaceuticals, LLC, Leder Laboratories, Inc., Starling Pharmaceuticals, Inc. ×3 申报 | 2015年2月10日 | — | 初始申报 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 18 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| AVSC · AMERICAN CENTURY ETF TRUST | 0.01% | 12850 NS | 2026年5月31日 | N-PORT |
| RSSL · Global X Funds | 0.01% | 5951 NS | 2026年4月30日 | N-PORT |
| ITWO · ProShares Trust | 0.00% | 639 NS | 2026年5月31日 | N-PORT |
| UWM · ProShares Trust | 0.00% | 500 NS | 2026年5月31日 | N-PORT |
| URTY · ProShares Trust | 0.00% | 506 NS | 2026年5月31日 | N-PORT |
| HDG · ProShares Trust | 0.00% | 13 NS | 2026年5月31日 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.00% | 4993 NS | 2026年4月30日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 2026年7月15日 | 每日 |
| VTI · VANGUARD INDEX FUNDS | — | — | 2026年7月15日 | 每日 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 2026年7月15日 | 每日 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | — | — | 2026年7月15日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 2026年7月15日 | 每日 |
| IWN · iShares Trust | — | — | 2026年8月17日 | 每日 |
| IWM · iShares Trust | — | — | 2026年8月18日 | 每日 |
| IWC · iShares Trust | — | — | 2026年8月18日 | 每日 |
| PRFZ · Invesco Exchange-Traded Fund Trust | — | — | 2026年7月13日 | 每日 |
| IBRN · iShares Trust | — | — | 2026年8月6日 | 每日 |
| QQQS · Invesco Exchange-Traded Fund Trus... | — | — | 2026年7月20日 | 每日 |